COMMUNIQUÉS West-GlobeNewswire

Nyxoah Reports First Quarter Financial and Operating Results
14/05/2025
REGULATED INFORMATION Nyxoah Reports First Quarter Financial and Operating Results Company On Track for Anticipated PMA Approval in the Second Quarter of 2025 Successfully Completed FDA Validation Requirements, Final [...]
Nyxoah Présente ses Résultats Financiers et Opérationnels du Premier Trimestre
14/05/2025
INFORMATIONS RÉGLEMENTÉES Nyxoah Présente ses Résultats Financiers et Opérationnels du Premier Trimestre La Société est en bonne voie pour obtenir l'autorisation de mise sur le marché au deuxième trimestre 2025 Les [...]
Noted Vaccine Researcher and Leader Kate O’Brien Awarded Sabin’s Gold Medal; Physician Livancliff Mbianke of Cameroon Receives Rising Star Award
14/05/2025
WASHINGTON, May 13, 2025 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the Albert B. Sabin Gold Medal to pediatrician Katherine O’Brien, MD, MPH, for her research on the pneumococcal vaccine and [...]
Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of Tinlarebant in adolescent Stargardt disease (STGD1) patients proceed [...]
HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
14/05/2025
MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen [...]
Anteris Announces Results for the First Quarter of 2025
13/05/2025
MINNEAPOLIS and BRISBANE, Australia, May 13, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, [...]
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
13/05/2025
Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures; Company ended the [...]
Claritas Neurocloud™ for Brain Imaging Analysis to Commence Commercialization on Execution of Partnership between Claritas and Qubiotech
13/05/2025
LONDON and SAO PAULO, May 13, 2025 (GLOBE NEWSWIRE) -- Claritas HealthTech Limited (“Claritas”), a healthcare technology company specializing in advanced medical image processing, segmentation, and AI solutions for the [...]
Applied Therapeutics Reports First Quarter 2025 Financial Results
13/05/2025
- Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society 2025 Annual [...]
Scientific Industries Reports Financial Results for First Quarter of Fiscal Year 2025
13/05/2025
BENCHTOP LAB EQUIPMENT SALES UP 5% FIRST PEER-REVIEWED PUBLICATION ON COMPANY’S DOTS MPS BIOPROCESSING PLATFORM RECORD NUMBER OF BIOPROCESSING SALES OPPORTUNITIES Investor Call to be held Wednesday, May 14 th at 11:00 a [...]
Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
13/05/2025
Significant advancements in preclinical pipeline for SIL204, with groundbreaking data demonstrating efficacy against both primary tumors and metastases in orthotopic models; strengthened financial position with over $9 [...]
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results
13/05/2025
Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases [...]
Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results
13/05/2025
All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are [...]
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
13/05/2025
- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximate ly 19 months with an encouraging safety profile - Well [...]
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
13/05/2025
Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual Meeting Granted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial [...]
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
13/05/2025
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merger to take place on [...]
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer
13/05/2025
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the [...]
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update
13/05/2025
Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma [...]
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
13/05/2025
Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025 CTA [...]

Pages